BREAST CANCER RECEPTORS, RADIONUCLIDES, &FLOW CYTOMETRY

$3,065P41FY2000RRNIH

University Of Calif-Los Alamos Nat Lab, Los Alamos NM

Investigators

Linked publications & trials

Paper 32395721 Paper 27530428 Paper 25419263 Paper 24206648 Paper 23968497 Paper 23809852 Paper 23478809 Paper 23331264 Paper 23224185 Paper 22465280 Paper 22312583 Paper 22239072 Paper 22219086 Paper 22155231 Paper 21954189 Paper 21248329 Paper 20938917 Paper 20692637 Paper 20662090 Paper 20498883 Paper 20373755 Paper 20143808 Paper 20035615 Paper 20006656 Paper 19852060 Paper 19816920 Paper 19770888 Paper 19298787 Paper 19021382 Paper 18770661 Paper 18307271 Paper 18248301 Paper 18189283 Paper 18186088 Paper 17924647 Paper 17712796 Paper 17680705 Paper 17400781 Paper 17212547 Paper 16969803 Paper 16828760 Paper 16604538 Paper 16419065 Paper 16316175 Paper 16229631 Paper 15924389 Paper 15812850 Paper 15786704 Paper 15764662 Paper 15717274 Paper 15634210 Paper 15290713 Paper 15229856 Paper 15229854 Paper 15180548 Paper 15131156 Paper 14994217 Paper 14736414 Paper 14616007 Paper 14608366 Paper 12944306 Paper 12844491 Paper 12815287 Paper 12815284 Paper 12809484 Paper 12626722 Paper 12596251 Paper 12424254 Paper 12116359 Paper 12011487 Paper 11988464 Paper 11924977 Paper 11878778 Paper 11827518 Paper 11826404 Paper 11813203 Paper 11777932 Paper 11700971 Paper 11641394 Paper 11602585 Paper 11598142 Paper 11309376 Paper 11277862 Paper 11170109 Paper 11122481 Paper 11042617 Paper 10938776 Paper 10818705 Paper 10728689

Abstract

We have met periodically throughout year 17 to develop a program in peptide receptor biology directed at treating Breast Cancer. Kvols is an expert in using the peptide somatostatin derivatized with radiolabels to diagnose and treat neuro-endocrine tumors. Atcher is an expert in radiobiology. Sklar and Prossnitz contribute expertise in receptor biology and flow cytometry. This project has begun by expressing neuroendocrine receptors in cells and detecting their expression with fluorescent peptides by flow cytometry. The next step in the plan is to examine the efficiency of specific peptide radionucleoides in killing both cell lines and cancer cells. The principles which arise are to be directed toward therapeutics in patients.

View original record on NIH RePORTER →